Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fuad Mirzayev

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
The European Respiratory Journal|April 9, 2021
New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health OrganizationKerri Viney, Nguyen Nhat Linh, Medea Gegia, et al.
Eclinicalmedicine|April 24, 2023
Global prevalence of hepatitis B or hepatitis C infection among patients with tuberculosis disease: systematic review and meta-analysisIoana D Olaru, Mina Beliz Meier, Fuad Mirzayev, et al.
Emerging Infectious Diseases|January 11, 2020
Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant TuberculosisJonathon R Campbell, Dennis Falzon, Fuad Mirzayev, et al.
The European Respiratory Journal|September 28, 2014
Multidrug-resistant tuberculosis around the world: what progress has been made?Dennis Falzon, Fuad Mirzayev, Fraser Wares, et al.
The European Respiratory Journal|August 20, 2021
World Health Organization treatment outcome definitions for tuberculosis: 2021 updateNguyen Nhat Linh, Kerri Viney, Medea Gegia, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 25, 2024
Treatment of Multidrug-resistant or Rifampicin-resistant Tuberculosis With an All-oral 9-month Regimen Containing Linezolid or Ethionamide in South Africa: A Retrospective Cohort StudyHannah Morgan, Norbert Ndjeka, Tasnim Hasan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2023
Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-AnalysisBelén P Solans, Agathe Béranger, Kendra Radtke, et al.
The European Respiratory Journal|January 28, 2022
Practices of therapeutic drug monitoring in tuberculosis: an international surveyIoana Margineanu, Onno Akkerman, Dario Cattaneo, et al.
Emerging Infectious Diseases|October 18, 2011
Drug-Resistant tuberculosis, KwaZulu-Natal, South Africa, 2001-2007Kristina Wallengren, Fabio Scano, Paul Nunn, et al.
Clinical Microbiology Reviews|November 4, 2025
Drug-resistant tuberculosis: a priority pathogen for enhanced public health research and practiceH Manisha Yapa, Emily L-H MacLean, Nicolas A Menzies, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
The European Respiratory Journal|April 9, 2021
New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health OrganizationKerri Viney, Nguyen Nhat Linh, Medea Gegia, et al.
Eclinicalmedicine|April 24, 2023
Global prevalence of hepatitis B or hepatitis C infection among patients with tuberculosis disease: systematic review and meta-analysisIoana D Olaru, Mina Beliz Meier, Fuad Mirzayev, et al.
Emerging Infectious Diseases|January 11, 2020
Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant TuberculosisJonathon R Campbell, Dennis Falzon, Fuad Mirzayev, et al.
The European Respiratory Journal|September 28, 2014
Multidrug-resistant tuberculosis around the world: what progress has been made?Dennis Falzon, Fuad Mirzayev, Fraser Wares, et al.
The European Respiratory Journal|August 20, 2021
World Health Organization treatment outcome definitions for tuberculosis: 2021 updateNguyen Nhat Linh, Kerri Viney, Medea Gegia, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 25, 2024
Treatment of Multidrug-resistant or Rifampicin-resistant Tuberculosis With an All-oral 9-month Regimen Containing Linezolid or Ethionamide in South Africa: A Retrospective Cohort StudyHannah Morgan, Norbert Ndjeka, Tasnim Hasan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2023
Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-AnalysisBelén P Solans, Agathe Béranger, Kendra Radtke, et al.
The European Respiratory Journal|January 28, 2022
Practices of therapeutic drug monitoring in tuberculosis: an international surveyIoana Margineanu, Onno Akkerman, Dario Cattaneo, et al.
Emerging Infectious Diseases|October 18, 2011
Drug-Resistant tuberculosis, KwaZulu-Natal, South Africa, 2001-2007Kristina Wallengren, Fabio Scano, Paul Nunn, et al.
Clinical Microbiology Reviews|November 4, 2025
Drug-resistant tuberculosis: a priority pathogen for enhanced public health research and practiceH Manisha Yapa, Emily L-H MacLean, Nicolas A Menzies, et al.
Pageof 3